Want to see TOVX full AI Analyst Report?
TOVX Stock Chart & Stats
$0.24
>-$0.01(-4.44%)
At close: 4:00 PM EDT
$0.24
>-$0.01(-4.44%)
Day’s Range― - ―
52-Week Range$0.16 - $0.86
Previous Close$0.22
Volume479.63K
Average Volume (3M)556.11K
Market Cap
$11.61M
Enterprise Value$3.70
Total Cash (Recent Filing)$11.34M
Total Debt (Recent Filing)$3.55M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,892,670
10 Day Avg. Volume588,155
30 Day Avg. Volume556,110
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$29.37M
Bulls Say, Bears Say
Bulls Say
VIRAGE2 Clinical ProgressionDosing the first patient advances VCN-01 into a focused proof-of-concept study and creates a defined path toward regimen optimization. If the trial confirms safety and pharmacodynamic activity, it could strengthen the case for a pivotal Phase 3 program in pancreatic cancer.
Prior Survival SignalA regulator-acknowledged survival benefit gives VCN-01 a meaningful clinical foundation beyond early laboratory findings. This evidence may improve the program’s credibility with clinicians, partners, and investors while supporting development in metastatic pancreatic cancer and other solid tumors.
High Gross Margin ProfileThe reported gross margin indicates that the company’s existing revenue stream is high-value when generated, offering potentially attractive unit economics if clinical programs eventually produce material commercial or partnered revenue. The benefit remains conditional on achieving scale.
Bears Say
Persistent Cash ConsumptionOngoing operating and free-cash-flow deficits show that development activities require substantial external funding rather than being supported by internally generated cash. Continued burn can restrict strategic flexibility and increase dependence on future financing while clinical milestones remain uncertain.
Minimal Commercial TractionThe very small revenue base indicates that Theriva has not yet demonstrated scalable commercial traction. With operating losses of roughly $11.6M and revenue far below the cost structure, the company remains dependent on successful development and future commercialization rather than an established business engine.
Equity Erosion And Dilution RiskA materially shrinking equity cushion reflects cumulative losses and leaves less balance-sheet capacity to absorb further development spending. Approved increases in authorized shares, stock awards, and warrant-related issuance could support funding but also create continuing dilution risk for existing shareholders.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.16 and its highest was $0.86 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $11.61M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Nov 17, 2026 which is in 71 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Aug 11, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.015.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.07.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,670 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went down -0.433%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
TOVX Stock 12 Month Forecast
Average Price Target
$1.00
▲(316.67% Upside)
Technical Analysis
Ownership Overview
0.57%
Insiders
0.90% Mutual Funds
0.35% Other Institutional Investors
97.12% Public Companies and
Individual Investors